These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25660586)

  • 1. Clinical Impact of Discordant Prescribing of Fluoroquinolones and Alternative Treatments in Escherichia coli Pyelonephritis.
    Hong MT; Seifert CF
    J Pharm Pract; 2016 Oct; 29(5):467-71. PubMed ID: 25660586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.
    Lee SS; Kim Y; Chung DR
    J Infect; 2011 Feb; 62(2):159-64. PubMed ID: 21055417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact.
    Shin J; Kim J; Wie SH; Cho YK; Lim SK; Shin SY; Yeom JS; Lee JS; Kweon KT; Lee H; Cheong HJ; Park SH; Park DW; Ryu SY; Chung MH; Yoo S; Pai H
    Microb Drug Resist; 2012 Apr; 18(2):169-75. PubMed ID: 22400491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
    Trials; 2015 Jan; 16():24. PubMed ID: 25623485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone.
    Lee S; Song DY; Cho SH; Kwon KT
    Microb Drug Resist; 2014 Feb; 20(1):39-44. PubMed ID: 23941639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.
    Wang SS; Ratliff PD; Judd WR
    Int J Clin Pharm; 2018 Feb; 40(1):143-149. PubMed ID: 29147962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
    de Lastours V; Chau F; Roy C; Larroque B; Fantin B
    J Antimicrob Chemother; 2014 Dec; 69(12):3393-400. PubMed ID: 25063781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
    Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
    Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients.
    Hobbs AL; Shea KM; Daley MJ; Huth RG; Jaso TC; Bissett J; Hemmige V
    J Antimicrob Chemother; 2016 Jun; 71(6):1665-71. PubMed ID: 26983859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential Use of Nitrofurantoin Over Fluoroquinolones for Acute Uncomplicated Cystitis and Outpatient Escherichia coli Resistance in an Integrated Healthcare System.
    Pedela RL; Shihadeh KC; Knepper BC; Haas MK; Burman WJ; Jenkins TC
    Infect Control Hosp Epidemiol; 2017 Apr; 38(4):461-468. PubMed ID: 28052786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis.
    Bedoin M; Cazorla C; Lucht F; Berthelot P; Boyer M; Carricajo A; Guérin T; Viallon A
    Med Mal Infect; 2014 May; 44(5):206-16. PubMed ID: 24794820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escherichia coli sequence type 131: epidemiology and challenges in treatment.
    Qureshi ZA; Doi Y
    Expert Rev Anti Infect Ther; 2014 May; 12(5):597-609. PubMed ID: 24694052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis.
    Peco-Antić A; Paripović D; Buljugić S; Spasojević-Dimitrijeva B; Cvetković M; Laban-Nestorović S; Milosevski-Lomić G
    Srp Arh Celok Lek; 2012; 140(5-6):321-5. PubMed ID: 22826985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urinary tract infection and fluoroquinolone resistance].
    Luisoni A; Cometta A
    Rev Med Suisse Romande; 2003 Mar; 123(3):155-7. PubMed ID: 15095700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones.
    Chiang SR; Shieh JM; Chen CH; Hsing SC; Wen SF; Wang JJ; Cheng KC; Chuang YC
    Infect Dis (Lond); 2016; 48(11-12):789-95. PubMed ID: 27329552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of gentamicin for women with community-acquired uncomplicated acute pyelonephritis caused by gentamicin-susceptible or -resistant Escherichia coli: 10-year experience.
    Wie SH; Kim HW; Chang UI
    Microb Drug Resist; 2013 Aug; 19(4):316-22. PubMed ID: 23473263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic therapy for acute uncomplicated pyelonephritis in women. Take resistance into account.
    Prescrire Int; 2014 Dec; 23(155):296-300. PubMed ID: 25629148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.